Zomedica Corp. announced the publication of a peer-reviewed research study favorably comparing the capabilities for the diagnosis of feline hyperthyroidism of its novel, point-of-care TRUFORMA Bulk Acoustic Wave (BAW) diagnostic platform to chemiluminescent immunoassay (CLIA) platforms currently broadly utilized by reference laboratories globally. The TRUFORMA diagnostic platform utilizes unique BAW technology that provides highly precise and sensitive measurements at levels that other diagnostic methods utilizing optical-based technologies cannot provide.

Currently, TRUFORMA in-clinic diagnostic systems provide accurate, rapid, and reliable diagnostic results to veterinarians to assist in their diagnosis and treatment of complex thyroid and adrenal conditions, canine non-infectious gastrointestinal disease and the first point-of-care assay for equine Cushing's disease, all providing reference lab quality with point of care convenience. Zomedica remains steadfast in its commitment to staying at the forefront of diagnostic options in veterinary care. It's unwavering dedication to advancing veterinary care is demonstrated through its ongoing clinical studies, which continue to advance veterinary science.